Entera Bio

Entera Bio Treasury Stock

The Treasury Stock of Entera Bio (ENTX) as of Oct 29, 2026 is 138.43 M USD. In the previous year, Treasury Stock was 121.97 M USD — a change of 13.50% (higher).

Treasury Stock

138.43 MUSD

YoY

13.50%

Last updated:

Treasury Stock of Entera Bio is 2025 138.43 M USD. Treasury Stock of Entera Bio was 2024 121.97 M USD. It decreases by 13.50% higher compared to the previous year.

The Entera Bio Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2018
49.17 M USD
Jan 1, 2019
63.39 M USD
Jan 1, 2020
68.78 M USD
Jan 1, 2021
104.95 M USD
Jan 1, 2022
107.21 M USD
Jan 1, 2023
114.73 M USD
Jan 1, 2024
121.97 M USD
Jan 1, 2025
138.43 M USD
The Entera Bio Treasury Stock history
YEARTreasury StockYoY
138.43 MUSD+13.50%
121.97 MUSD+6.31%
114.73 MUSD+7.01%
107.21 MUSD+2.15%
104.95 MUSD+52.58%
68.78 MUSD+8.51%
63.39 MUSD+28.92%
49.17 MUSD+1,623.55%
2.85 MUSD+14.81%
2.49 MUSD+6.42%
2.34 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Treasury Stock of Entera Bio is 138.43 M USD in 2025.

Treasury Stock of Entera Bio changed from 121.97 M USD to 138.43 M USD, representing a 13.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Entera Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Entera Bio

All Key Metrics — Entera Bio